Clinical trials: CDD, open to volunteers
CDKL5 Deficiency Disorder
Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old
This study will assess the efficacy, safety, and tolerability of ganaxolone (GNX) compared with placebo (PBO) as adjunctive therapy to the participant's standard anti-epileptic medication for the treatment of seizures in…
- Trial name
- NCT05249556
- Testing
- Ganaxolone
- Volunteers
- 20 people
- Sponsor
- Immedica Pharma AB
Advanced Squamous Non-Small Cell Lung Cancer
A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer
This is a multicenter phase II study enrolling treatment- naïve patients with metastatic or recurrent squamous carcinoma of the lung
- Trial name
- CECYDE (NCT07418931)
- Testing
- Cemiplimab 350 mg IV, Paclitaxel 200 mg/sqm IV, Carboplatin AUC 5 IVa
- Where
- 15 sites in Italy
- Volunteers
- 108 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
CDKL5, CDKL5 Deficiency Disorder
International CDKL5 Clinical Research Network
Pathogenic variants in the Cyclin-dependent kinase like 5 (CDKL5) gene cause CDKL5 deficiency disorder (CDD, MIM 300672, 105830), a severe developmental and epileptic encephalopathy associated with cognitive and motor impairments…
- Conditions
- CDKL5, CDKL5 Deficiency Disorder, CDD
- Trial name
- ICCRN (NCT05558371)
- Testing
- No intervention.
- Where
- 9 sites in United States, Australia
- Volunteers
- 1,000 people
- Sponsor
- University of Colorado, Denver